ATE251119T1 - Cyclopropyl-derivate mit pharmazeutischen eigenschaften - Google Patents

Cyclopropyl-derivate mit pharmazeutischen eigenschaften

Info

Publication number
ATE251119T1
ATE251119T1 AT98302693T AT98302693T ATE251119T1 AT E251119 T1 ATE251119 T1 AT E251119T1 AT 98302693 T AT98302693 T AT 98302693T AT 98302693 T AT98302693 T AT 98302693T AT E251119 T1 ATE251119 T1 AT E251119T1
Authority
AT
Austria
Prior art keywords
optionally substituted
alkyl
cycloalkyl
substituted phenyl
alkynyl
Prior art date
Application number
AT98302693T
Other languages
English (en)
Inventor
Tercero Concepcion Pedregal
Cano Ivan Collado
Ruiz Angel Mazon
Original Assignee
Lilly Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Sa filed Critical Lilly Sa
Application granted granted Critical
Publication of ATE251119T1 publication Critical patent/ATE251119T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT98302693T 1997-04-08 1998-04-06 Cyclopropyl-derivate mit pharmazeutischen eigenschaften ATE251119T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009700736A ES2131463B1 (es) 1997-04-08 1997-04-08 Derivados de ciclopropilglicina con propiedades farmaceuticas.

Publications (1)

Publication Number Publication Date
ATE251119T1 true ATE251119T1 (de) 2003-10-15

Family

ID=8298874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98302693T ATE251119T1 (de) 1997-04-08 1998-04-06 Cyclopropyl-derivate mit pharmazeutischen eigenschaften

Country Status (7)

Country Link
US (1) US6172058B1 (de)
EP (1) EP0870760B1 (de)
JP (1) JPH10287633A (de)
AT (1) ATE251119T1 (de)
CA (1) CA2234025A1 (de)
DE (1) DE69818538T2 (de)
ES (2) ES2131463B1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE287871T1 (de) 1999-06-03 2005-02-15 Lilly Sa Modulatoren von anregbaren aminosäurerezeptoren
EP1189873A1 (de) 1999-06-03 2002-03-27 Lilly, S.A. Modulatoren von durch aminosäuren anregbare rezeptoren
AU6455501A (en) * 2000-05-31 2001-12-11 Lilly Co Eli Excitatory amino acid receptor modulators
US7125871B2 (en) * 2000-05-31 2006-10-24 Eli Lilly And Company Excitatory amino acid receptor modulators
US7081481B2 (en) * 2000-05-31 2006-07-25 Eli Lilly And Company Excitatory amino acid receptor modulators
EP1289935A1 (de) * 2000-05-31 2003-03-12 Eli Lilly And Company Modulatoren der exzitatorischen aminosäurerezeptoren
PL370764A1 (en) * 2001-10-05 2005-05-30 Combinatorx, Incorporated Combinations for the treatment of immunoinflammatory disorders
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
MX2010005110A (es) * 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2013043744A2 (en) 2011-09-21 2013-03-28 Inception 1, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
US9499586B2 (en) * 2012-10-16 2016-11-22 Hong Kong Baptist University Anticancer and anti-obesity cyclic peptide agents
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (de) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung
SI3096790T1 (sl) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne aleostrične modulatorje ali ortosterične agoniste metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
AR108326A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959463A (en) 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
CA1305177C (en) * 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
JP3481975B2 (ja) 1992-09-08 2003-12-22 サントリー株式会社 （２ｓ，１’ｓ，２’ｒ）−２−（２−カルボキシ−３−置換オキシメチルシクロプロピル）グリシン及びその製造法
GB9325368D0 (en) * 1993-12-10 1994-02-16 Univ Bristol Organic compounds
ES2139928T3 (es) 1994-09-08 2000-02-16 Lilly Co Eli Antagonistas de receptores de aminoacidos de excitacion.
JPH08301825A (ja) * 1995-03-07 1996-11-19 Suntory Ltd ３’−置換−（２−カルボキシシクロプロピル）グリシン
IT1276153B1 (it) * 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato
WO1998000391A1 (fr) 1996-06-28 1998-01-08 Nippon Chemiphar Co., Ltd. Derives de cyclopropylglycine et agoniste du recepteur du l-glutamate du type a regulation metabolique

Also Published As

Publication number Publication date
US6172058B1 (en) 2001-01-09
ES2209063T3 (es) 2004-06-16
CA2234025A1 (en) 1998-10-08
EP0870760B1 (de) 2003-10-01
EP0870760A1 (de) 1998-10-14
DE69818538D1 (de) 2003-11-06
ES2131463B1 (es) 2000-03-01
DE69818538T2 (de) 2004-08-05
JPH10287633A (ja) 1998-10-27
ES2131463A1 (es) 1999-07-16

Similar Documents

Publication Publication Date Title
DE69818538D1 (de) Cyclopropyl-Derivate mit pharmazeutischen Eigenschaften
ATE102923T1 (de) Isoindolonderivate, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NZ228889A (en) Fused tri- or tetracyclic heterocyclic compounds and pharmaceutical compositions
DE69433752T2 (de) Bicyclische Carbonsäuren und deren Derivate als NEP und ACA Inhibitoren
DE69325944D1 (de) s-Triazinderivate als Lichtschutzmittel
DE69013836D1 (de) Benzimidazolverbindungen und deren Anwendung.
ES2179881T3 (es) Antagonistas de endotelina.
NO931917D0 (no) Farmasoeytiske forbindelser
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
DK506587A (da) Imidderivater
EA199700160A1 (ru) Производные индола в качестве антагонистов eaa
FR2630328B1 (fr) Derive de l'histamine, sa preparation et son application en therapeutique
SE9100920D0 (sv) New active compounds
NO306510B1 (no) Androsteroner, anvendelse derav og farmasöytisk formulering
ES2179254T3 (es) 1-poliarilpirazoles plaguicidas.
FI94354C (fi) Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi
DE69416191D1 (de) Spiropyran-Derivate mit photochromischen Eigenschaften
ATE122562T1 (de) Derivate von penciclovir zur behandlung von hepatitis-b-infektionen.
FI894068A (fi) Sulfonamider med tetrazolylrest, foerfarande foer deras tillverkning och laekemedel.
FI932691A (fi) Nya benzyl- och benzhydrylalkoholer
ES2076477T3 (es) Nuevos derivados de indol e indolina.
DE69116251D1 (de) Verfahren zur Herstellung von 6-(substituiertes Aminopropionyl)-Derivaten von Forskolin
EA200000168A1 (ru) Фармацевтическая композиция, снижающая продуцирование белка мср-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties